Covid 19 Research using Clinical Trials (Home Page)
FavipiravirWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (18)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug546 | Niclosamide Wiki | 0.41 |
| drug583 | Other drugs Wiki | 0.41 |
| drug600 | Patient management suffering of coronavirus infection Wiki | 0.41 |
| drug412 | Imatinib Wiki | 0.41 |
| drug902 | Vitamins Wiki | 0.41 |
| drug778 | Standard of care treatment Wiki | 0.41 |
| drug828 | Telmisartan Wiki | 0.29 |
| drug447 | Ivermectin Wiki | 0.29 |
| drug549 | Nitazoxanide Wiki | 0.29 |
| drug361 | Hydroxychloroquine (HCQ) Wiki | 0.24 |
| drug169 | Camostat Mesilate Wiki | 0.24 |
| drug627 | Placebo oral tablet Wiki | 0.18 |
| drug190 | Chloroquine Wiki | 0.17 |
| drug360 | Hydroxychloroquine Wiki | 0.15 |
| drug691 | Remdesivir Wiki | 0.12 |
| drug632 | Placebos Wiki | 0.11 |
| drug82 | Azithromycin Wiki | 0.09 |
| drug616 | Placebo Wiki | 0.04 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000077062 | Burnout, Psychological NIH | 0.29 |
| D003141 | Communicable Diseases NIH | 0.24 |
| D013315 | Stress, Psychological NIH | 0.24 |
| D007239 | Infection NIH | 0.17 |
| D014777 | Virus Diseases NIH | 0.13 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.11 |
| D018352 | Coronavirus Infections NIH | 0.09 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 6 clinical trials
Clinical Trials
1 A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type
This study evaluates treatment with Favipiravir combined with supportive care for adult patients with COVID-19-moderate type.
NCT04336904 COVID-19 Drug: Favipiravir Other: Placebo
Primary Outcomes
Description: The duration from start of treatment (Favipiravir or placebo) to normalization of pyrexia, respiratory rate and SPO2 and relief of cough (where there are relevant abnormal symptoms at enrolment) that is maintained for at least 72 hours.
Measure: Time from randomization to clinical recovery Time: 90 daysSecondary Outcomes
Description: 1. Time from randomization to negativity in RT-PCR nucleic acid test for 2019-nCov within 28 days of randomization;
Measure: Time from randomization to negativity in RT-PCR nucleic acid test Time: 28 daysDescription: Incidence of deterioration/aggravation of pneumonia (defined as SPO2≤93% or PaO2/FiO2 ≤300 mmHg or distressed RR≥30/min without oxygen inhalation and requiring oxygen therapy or more advanced breath support) within 28 days of randomization;
Measure: Incidence of deterioration/aggravation of pneumonia Time: 28 daysDescription: Time from randomization to resolution of pyrexia (defined the same as for the primary efficacy variable; applicable to subjects with pyrexia at enrolment) within 28 days of randomization;
Measure: Time from randomization to resolution of pyrexia Time: 28 daysDescription: Time from randomization to relief of cough (defined the same as for the primary efficacy variable; applicable to subjects with cough at enrolment) within 28 days of randomization; It is recommended that the severity of cough be graded as per NCI-CTCAE v5.0: Mild: Requires non-prescription treatment; Moderate: Requires medication treatment; limits instrumental activities of daily living; Severe: Limits self-care activities of daily living
Measure: Time from randomization to relief of cough Time: 28 daysDescription: Time from randomization to relief of dyspnoea (defined as subject-perceived improvement or resolution of dyspnoea; applicable to subjects with dyspnoea at enrolment) within 28 days of randomization;
Measure: Time from randomization to relief of dyspnoea Time: 28 daysDescription: 6. Rate of auxiliary oxygen therapy or non-invasive ventilation within 28 days of randomization
Measure: Rate of auxiliary oxygen therapy Time: 28 daysDescription: ICU admission rate within 28 days of randomization
Measure: ICU admission rate Time: 28 daysDescription: All-cause mortality within 28 days of randomization
Measure: Mortality Time: 28 days2 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19
COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.
NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs
Primary Outcomes
Description: the estimated number of patients with decreased viral load
Measure: Number of patients with decreased viral load Time: 6 months3 A Phase 2 Randomized, Open Label Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19
The objective of this study is to evaluate the efficacy of oral favipiravir compared with SOC in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.
NCT04346628 COVID Drug: Favipiravir Other: Standard of care treatment
Primary Outcomes
Description: Time in days from randomization to a negative result of nasopharyngeal and/or oropharyngeal and/or salivary swab.
Measure: Time until cessation of oral shedding of SARS-CoV-2 virus Time: Up to 28 daysSecondary Outcomes
Description: Clinical worsening will be determined by clinician assessment.
Measure: Count of participants with clinical worsening of COVID-19 disease Time: Up to 28 daysDescription: Viral load will be assessed as the TCID50 (Median Tissue Culture Infectious Dose) over time.
Measure: Sars-CoV-2 viral load Time: Up to 28 daysMeasure: Count of participants with development of SARS-CoV-2 antibodies Time: Up to 28 days
Measure: Time until cessation of symptoms Time: Up to 28 days
Description: Cmax is a pharmacokinetic parameter that measures the maximum concentration of drug in plasma.
Measure: Cmax of favipiravir Time: Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)Description: Cmin is a pharmacokinetic parameter that measures the minimum concentration of drug in plasma.
Measure: Cmin of favipiravir Time: Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)4 Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment
Faviprevir in COVID-19 treatment
NCT04351295 COVID Drug: Favipiravir Drug: Placebos
Primary Outcomes
Description: The total number of patients with viral cure
Measure: Number of patients with viral cure Time: 6 months5 Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19): a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)
This trial will estimate the efficacy and tolerance of several experimental treatments to prevent hospitalization or death in outpatients aged 65 years or above with Symptomatic SARS-CoV-2 Infection (COVID-19).
NCT04356495 Corona Virus Infection Sars-CoV2 Dietary Supplement: Vitamins Drug: Hydroxychloroquine Drug: Imatinib Drug: Favipiravir Drug: Telmisartan MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Virus Diseases
Primary Outcomes
Measure: Proportion of participants with an occurrence of hospitalization Time: From inclusion (day0) to day 14Description: Proportion of participants with an occurrence of death
Measure: Death Time: From inclusion (day0) to day 14Secondary Outcomes
Measure: Proportion of hospitalizations, overall and by cause, in each group Time: From inclusion (day0) to day 28Description: Proportion of deaths, overall and by cause, in each group
Measure: Death and causes of death Time: From inclusion (day0) to day 28Measure: Proportion of intensive care hospitalizations, overall and by cause, in each group Time: From inclusion (day0) to day 28
Measure: Proportion of participants with negative nasopharyngeal SARS-CoV-2 RT-PCR Time: day 7 and day 14
Measure: Proportion of participants with a loss of autonomy evaluated by the ADL and IADL scale Time: day 14 and day 28
Description: Evolution of Haematological markers in each group : Complete Blood Count, prothrombin level, INR
Measure: Haematological markers evolution Time: from inclusion (day 0) to day 7 and day 14Description: Evolution of Biochemical markers in each group : ferritin, serum creatinine, urea, sodium, potassium, chlorine, calcium, magnesium, albumin, bicarbonates / tCO2, LDH, CPK, ASAT, ALAT, uricemia
Measure: Biochemical markers evolution Time: from inclusion (day 0) to day 7 and day 14Description: Evolution of Inflammatory markers in each group : PCT, CRP
Measure: Inflammatory markers evolution Time: from inclusion (day 0) to day 7 and day 14Description: Evolution of immunological markers in each group : B ans T Cells phenotypic profiles
Measure: Immunological markers evolution Time: from inclusion (day 0) to day 7 and day 14Description: Number and proportion of grade 1,2,3,4 adverse events in each group
Measure: Adverse events Time: from inclusion (day 0) to day 14Description: Number and proportion of grade 1,2,3,4 adverse events in each group
Measure: Adverse reactions Time: from inclusion (day 0) to day 14Description: Plasma concentration of the study drugs at D7
Measure: Plasma concentration Time: day 7Description: Acceptability of the treatment by participant will be assessed with an interview
Measure: Acceptability of the treatment Time: from inclusion (day 0) to day 106 Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial
The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.
NCT04359615 COVID-19 Drug: Favipiravir Drug: Hydroxychloroquine
Primary Outcomes
Description: Improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever came first.
Measure: Time to clinical improvement Time: From date of randomization until 14 days later.Secondary Outcomes
Description: If the patient dies, we have reached an outcome.
Measure: Mortality Time: From date of randomization until 14 days later.Description: Pulse-oxymetry
Measure: oxygen saturation by pulse oximetry (SpO2) Improvement Time: Days 1, 2, 3, 4, 5, 6, 7 and 14.Description: Incidence of new mechanical ventilation use
Measure: Incidence of new mechanical ventilation use Time: From date of randomization until 14 days later.Description: Duration of hospitalization (days)
Measure: Duration of hospitalization Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 14 days.Description: With incidence of any serious adverse effects, the outcome has happened.
Measure: Cumulative incidence of serious adverse events Time: Days 1, 2, 3, 4, 5, 6, 7 and 14.